TIL（肿瘤浸润淋巴细胞）与乳腺放疗：国际免疫肿瘤生物标志物工作组展望

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

放疗增强新型溶瘤疱疹病毒 VG161 的溶瘤效果并放大其在乳腺癌中的抗肿瘤免疫

Radiotherapy Enhances the Oncolytic Efficacy of the Novel Oncolytic Herpesvirus VG161 and Amplifies Its Antitumor Immunity in Breast Cancer.

HER2 阴性乳腺癌中联合贝伐珠单抗化疗后 CD8 阳性淋巴细胞的变化

Changes in CD8-positive lymphocytes following chemotherapy with concomitant bevacizumab in HER2-negative breast cancer.

含贝伐珠单抗的化疗似乎可增强原发乳腺肿瘤中 CD8 阳性 TIL 的浸润，这可能有助于改善局部肿瘤消退和更好的治疗结局。

CFD 过表达通过 NOSTRIN 与 eNOS 信号通路抑制 CESC 进展并增强 TIL 疗法疗效

CFD overexpression inhibits CESC progression and enhances TIL therapy efficacy via NOSTRIN and eNOS signaling pathway.

预测性 14 基因特征与 FLI1 抑制克服三阴性乳腺癌中 TIL（肿瘤浸润淋巴细胞）功能障碍

A predictive 14-gene signature and FLI1 inhibition overcome tumor-infiltrating lymphocyte dysfunction in triple-negative breast cancer.

基于免疫相关基因联合肿瘤突变负荷与 T 细胞浸润的三阴性乳腺癌预后模型鉴定

Identification of a prognostic model using immune related genes combined with tumour mutational burden and T cell infiltration in triple-negative brea

乳腺癌免疫治疗：从检查点抑制到新兴细胞治疗

Immunotherapies for Breast Cancer: From Checkpoint Inhibition to Emerging Cellular Therapies.

三阴性乳腺癌中的 TIL（肿瘤浸润淋巴细胞）治疗：从机制探索到临床转化

Tumor-infiltrating lymphocyte therapy in triple-negative breast cancer: from mechanistic exploration to clinical translation.

TIL（肿瘤浸润淋巴细胞）动态变化作为 luminal 型乳腺癌新辅助治疗反应的生物标志物

Tumor-Infiltrating lymphocyte dynamics as biomarkers of neoadjuvant treatment response in luminal breast cancer.

理解 TILs：胃食管癌 TIL（肿瘤浸润淋巴细胞）形态学评估建议——代表国际免疫肿瘤生物标志物工作组报告

Making sense of TILs: recommendations for morphological assessment of tumour-infiltrating lymphocytes in gastro-oesophageal carcinoma: A report on beh